RSS   Newsletter   Contact   Advertise with us
Post Online Media

Pfenex appoints Evert Schimmelpennink as CEO

Evert SchimmelpenninkPfenex, a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, appoints Evert Schimmelpennink as chief executive officer, president, and secretary.
Article continues below

READ MORE Pfenex announces election of John Taylor to its board

Mr. Schimmelpennink was also appointed to serve as a Class III member of the board of directors effective August 3, 2017.

Mr. Schimmelpennink brings to Pfenex a broad base of biotechnology and pharmaceutical experience with strategic and functional expertise across corporate development, commercial operations, manufacturing and R&D.

Prior to joining Pfenex, he served as the Chief Executive Officer of Alvotech, a biosimilar development company, Vice President Global Injectables at Pfizer and Vice President – Global Generics of Hospira.

Mr. Schimmelpennink received a Masters in bioprocess engineering from the Wageningen University in the Netherlands.



We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy